A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from birth
- Coverage achievable with 2-week gap before early delivery
- Vaccination during the third trimester still offers meaningful infant protection
Strong evidence from current research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing strong and reliable data of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and prospective parents with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast highlights the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology assessed real-world outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine performs when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it extremely challenging for affected infants to feed and breathe effectively. Parents frequently observe their babies fighting for breath, their chests heaving as they attempt to draw adequate oxygen into their weakened respiratory system. Whilst most infants recover with supportive care, a limited though important group succumb from RSV-related complications yearly, making vaccination as prevention a vital health service priority for protecting the youngest and most vulnerable members of society.
- RSV produces lung inflammation, resulting in serious respiratory problems in infants
- Approximately half of newborns acquire the virus during their first few months alive
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK babies need serious hospital treatment for RSV each year
- Few infants succumb to RSV complications annually in the UK
Take-up rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have emphasised the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.
The messaging from public health bodies stays clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts rolling out varied communication campaigns to connect with pregnant women
- Geographic variations in vaccination coverage levels in different parts of England demand focused enhancement
- Regional health providers adapting programmes to meet specific population needs
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% decrease in admissions means thousands of infants shielded from serious illness. Parents no more face the upsetting situation of seeing their babies struggle for breath or difficulty feeding, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal breathing health, providing expectant mothers a preventative option to shield their most at-risk babies during those critical early months.
For families like that of Malachi, whose serious RSV infection caused profound brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab underscores the life-altering consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to women in pregnancy during their late pregnancy, changing what was once an inevitable seasonal threat into a manageable risk.